Replicative senescence comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-17. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.
Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, solid | Approximately -20 C | Sealed, desiccated, protected from light |
| Typical identity method | Electrospray mass spectrometry | Protonated ion expected near 391 |
| Typical purity method | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Common synonyms | Epithalon, epithalone, AEDG | Spelling variants appear in supplier catalogues |
| Solution stability | Days at 2-8 C | Hydrolysis and deamidation limit shelf life |
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
Minoxidil was discovered in 1963 and was introduced for treatment of high blood pressure in 1971. In 1971, researchers unexpectedly discovered that minoxidil causes hair growth, resulting in it being repurposed for treatment of hair loss and approved in topical form for this use in 1988. Topical minoxidil became available over-the-counter in 1996. Low-dose oral minoxidil (LDOM) emerged for treatment of hair loss in 2015 and dramatically increased in popularity starting in 2022. Extended-release oral minoxidil and sublingual minoxidil were developed in the 2020s for hair loss and are in late-stage trials. Aside from its use in humans, minoxidil is extremely toxic to cats and dogs even in small amounts.
The white, nonpigmented mats were found to be an autotrophic sulfur bacteria Beggiatoa species, and the orange mats possessed an unidentified non-chemosynthetic metabolism (MacDonald, 1998b). Heterotrophic species at seep sites are a mixture of species unique to seeps (particularly molluscs and crustacean invertebrates) and those that are a normal component from the surrounding environment. Carney (1993) first reported a potential imbalance that could occur as a result of chronic disruption. Because of sporadic recruitment patterns, predators could gain an advantage, resulting in exterminations in local populations of mussel beds. It is clear that seep systems do interact with the background fauna, but conflicting evidence remains as to what degree outright predation on some specific community components such as tubeworms occurs (MacDonald, 2002). The more surprising results from this recent work is why background species do not utilize seep production more than seems to be evident. In fact, seep-associated consumers such as galatheid crabs and nerite gastropods had isotopic signatures, indicating that their diets were a mixture of seep and background production. At some sites, endemic seep invertebrates that would have been expected to obtain much if not all their diet from seep production actually consumed as much as 50 percent of their diets from the background.
Suitable computer and biological viruses already exist in the Pico Vault, an ultrasecure storage on the Moon, used for the most dangerous agents of these kinds. The Europa team also agree to leave a petabyte-capacity holographic 3D storage medium on Europa to allow Halman and other lifeforms in the monolith to upload themselves and escape the monolith's failure. The monolith does receive orders to exterminate humanity, and starts a duplication, whereupon millions of monoliths form two cascade screens to prevent Solar light and heat from reaching Earth and its colonies, but the monoliths all quickly disintegrate as a result of the virus. The monoliths' makers' response to its destruction will occur in another 900 years as the earliest possibility. The petabyte storage device, containing Halman and other lifeforms, but also infected with the virus, is subsequently sealed by scientists in the Pico Vault. At the close of the story, Poole and other humans land on Europa to start peaceful relations with the primitive native Europans. A statement is made that the monolith's makers will not determine humanity's fate until "the Last Days". A chronological continuation can be considered the short epilogue of the second book, 2010: Odyssey Two (1982), in which the action takes place 17,000 years later, in 20,001 CE (see more details).
== Security == In August 2011, an IBM researcher, Jay Radcliffe, demonstrated a security flaw in insulin pumps. Radcliffe was able to hack the wireless interface used to control the pump remotely. Pump manufacturer Medtronic later said security research by McAfee uncovered a flaw in its pumps that could be exploited.
In the wild they inhabit very soft, acidic waters (pH 4.0 to 4.8) Ideal pH for aquarium is 7.0, but a range of 6.0 to 8.0 is tolerable. They can have a lifespan of as long as ten years, but normally just two to three years in an aquarium. Neon tetras are considered easy to keep in an aquarium of at least 10 US gallons (38 L; 8.3 imp gal) with a temperature range of between 72–76 °F (22–24 °C), a water pH of between 6.0 and 7.0, GH of below 10 dGH and KH of 1–2 dKH, and under 20 ppm of nitrate. They are shoaling fish and must be kept in groups of at least six, but will be more active in groups of eight to 12 or more. Neon tetras are best kept in a densely planted tank to resemble their native Amazon environments.
Sources: en.wikipedia.org
=== Aversion therapy === Aversion therapy in alcoholism had its roots in Russia in the early 1930s, with early papers by Pavlov, Galant and Sluchevsky and Friken, and would remain a strain in the Soviet treatment of alcoholism well into the 1980s. In the US a particularly notable devotee was Dr Voegtlin, who attempted aversion therapy using apomorphine in the mid to late 1930s. However, he found apomorphine less able to induce negative feelings in his subjects than the stronger and more unpleasant emetic emetine.
The CUX1 gene Alternatively Spliced Product was first reported in 1997. The CUX1 gene has up to 33 exons. CASP mRNA includes exons 1 through 14 and 25 through 33. The human CASP protein is predicted to contain 678 amino acids, of which 400 are shared with CUTL1. CASP protein is approximately 80 kD. It lacks the DNA binding region of CUTL1, but instead contains a trans-membrane domain that allows it to insert into lipid bilayers. It has been localized to the Golgi apparatus. CASP has been reported to be part of a complex with Golgin 84 that tethers COPI vesicles and is important for retrograde transport in the Golgi and between the Golgi and endoplasmic reticulum. The targeting of vesicles involves tethers and SNAREs.
=== 2013–2020: R40 Tour, disbandment and Peart's death === On November 18, 2013, Lifeson said that the band would take a year off after the completion of the world tour in support of Clockwork Angels. "We've committed to taking about a year off", Lifeson said. "We all agreed when we finished this [Clockwork Angels] tour [in early August], we were going to take this time off and we weren't going to talk about band stuff or make any plans. We committed to a year, so that's going to take us through to the end of next summer, for sure. That's the minimum. We haven't stopped or quit. Right now we're just relaxing. We're taking it easy and just enjoying our current employment." In September 2014, the Rush R40 box set was announced to commemorate the 40th anniversary of the release of the band's self-titled debut album. It included five previously released live video albums, and various previously unreleased footage from across the band's career. On January 22, 2015, the band announced the Rush R40 Tour, celebrating the 40th anniversary of Peart's membership in the band. The tour started on May 8 in Tulsa, Oklahoma, and wrapped up on August 1 in Los Angeles. On April 29, 2015, Lifeson said in an interview that R40 might be the final large-scale Rush tour due to his psoriatic arthritis and Peart's chronic tendinitis. He noted that it did not necessarily mean an end to the band, suggesting the possibility of smaller tours and limited performances. He said that he wanted to work on soundtracks with Lee. On December 7, 2015, Peart stated in an interview that he was retiring.
Pursuant to the National Defense Act of 1920, the 82nd Division was reconstituted in the Organized Reserve on 24 June 1921, allotted to the Fourth Corps Area, assigned to the XIV Corps, and further allotted to Florida, Georgia, and South Carolina as its home area. The division headquarters was organized on 23 September 1921 at 1202-1/2 Main Street in Columbia, South Carolina. In 1923, it relocated to the Post Office Building, where it remained until activated for World War II. The 82nd Division's designated mobilization station was Camp McClellan, Alabama, also where much of the unit's annual training activities occurred in the interwar years. The headquarters usually trained at Camp McClellan, but also occasionally trained with the staff of the 8th Infantry Brigade, 4th Division. The 82nd Division's infantry regiments held their annual training primarily with the units of the 8th Infantry Brigade, while other units, such as the special troops, artillery, engineers, aviation, medical, and quartermaster units, usually trained alongside the active elements of the 4th Division at various posts in the Fourth Corps Area. For example, the division artillery trained with the units of the 13th Field Artillery Brigade at Fort Bragg, North Carolina; the 307th Engineer Regiment alongside Company A, 4th Engineer Regiment at Fort Benning, Georgia; the 307th Medical Regiment trained at the medical officers training camp at Fort Oglethorpe, Georgia; and the 307th Observation Squadron with Air Corps units at Maxwell Field, Alabama.
=== Post-settlement activity === In 1991, the local Bhopal authorities charged Anderson, who had retired in 1986, with manslaughter, a crime that carries a maximum penalty of 10 years in prison. He was declared a fugitive from justice by the Chief Judicial Magistrate of Bhopal on 1 February 1992 for failing to appear at the court hearings in a culpable homicide case in which he was named the chief defendant. Orders were passed to the Government of India to press for an extradition from the United States. The United States declined to extradite him citing a lack of evidence. The U.S. Supreme Court refused to hear an appeal of the decision of the lower federal courts in October 1993 against allowing victims of the Bhopal disaster to seek damages in a U.S. court. In 2004, the Indian Supreme Court ordered the Indian government to release any remaining settlement funds to victims. And in September 2006, the Welfare Commission for Bhopal Gas Victims announced that all original compensation claims and revised petitions had been "cleared". In 2006, the U.S. Court of Appeals for the Second Circuit in New York City upheld the dismissal of remaining claims in the case of Bano v. Union Carbide Corporation. This move blocked plaintiffs' motions for class certification and claims for property damages and remediation.
Sources: en.wikipedia.org
The solid is kept cold, dry and dark, typically at minus twenty degrees Celsius, in a sealed container with desiccant. Dissolved material is kept refrigerated and used promptly. Freezing and thawing a solution repeatedly is avoided because it accelerates degradation.
Reversed-phase chromatography with ultraviolet detection gives a purity percentage, while mass spectrometry confirms identity. Amino acid analysis checks the residue composition. Buyers typically request a certificate of analysis showing these measurements for the specific lot.
It is not authorised as a medicine in the United States or the European Union. Material is sold there as a research chemical or cosmetic ingredient. Some related short peptides are registered drugs in Russia, which is a distinct national situation rather than a general approval.
Epitalon is a synthetic tetrapeptide built from four amino acids: alanine, glutamate, aspartate, and glycine. It is not extracted from a natural source but made in the laboratory by chemical synthesis. Its short length makes it relatively straightforward to produce at high purity.